Clinical setback in lung cancer for key Chi-Med project
This article was originally published in Scrip
Executive Summary
Hutchison China MediTech(Chi-Med) has put the clinical development of one of its most advanced pipeline projects on hold after an interim analysis of data from a Chinese Phase II study showed it to have missed an efficacy endpoint.